It’s time for the pharmaceutical industry to release the list every year. This year’s list has a lot to watch: Gilead’s hepatitis C field has successfully achieved “Squid Jumping Dragon Gateâ€, and the generic giant Teva’s list has shown its face for the first time. Lilly has been hit hard by imitation. Top 10 in the list. And the next 2015 will have more expectations: Ateves's $66 billion acquisition of Elgin will be strong in the top 10, while the GlaxoSmithKline-Nova-Lilly three giants will play their assets this year. Moved, the list will be reshuffled.
Recently, the famous pharmaceutical website FiercePharma announced the "2014 global pharmaceutical giant revenue TOP15 list". As always, industry giants such as Johnson & Johnson (JNJ), Novartis (Roche), and Pfizer (Pfizer) are still in the top positions on the list, but the changes in the TOP10 this year are not small, last year. Eli Lilly, ranked 10th, fell out of the top 10 this time, and its position was replaced by hepatitis C leader Gilead, whose company's hepatitis C star drug Sovaldi sold $10 billion in global sales last year. It’s soft to make other pharmaceutical giants particularly jealous, and its revenue has doubled from the previous year, from $10.8 billion in 2013 to $24.5 billion in 2014.
Other regulars in the top 10 of the TOP list, such as Sanofi, Merck & Co, GSK, AZN, and Bayer, 2014 Operating income has not changed much from last year, and there has been no major change in rankings. However, Gilead is not the only biotech giant to achieve the "Squid Jumping Dragon Gate". Since many companies' revenues in 2014 were around $20 billion, this year's list expanded to TOP15, which brought Amgen and AbbVie to the list, while Lilly fell to 14. The pharmaceutical giant Bristol-Myers Squibb (BMS), which has been absent for several years on this list, re-emerged in the 15th in 2014. The generic drug giant Teva, which has long been ignored by this list, ranked 11th in the list this year. The company's revenue in 2014 reached 20.3 billion US dollars.
In addition, Bristol-Myers Squad's anti-psychotic drug Abilify suffered a patent cliff in 2015, and Teva's best-selling multiple sclerosis drug Copaxone will also face generic damage, which seems destined to face a big wash in the pharmaceutical industry in 2015. brand. However, the biggest change will occur in frequent visitors to this list, with GlaxoSmithKline (GSK) and Novartis recently completing asset swap transactions. Actavis is another company that deserves special expectations. The company will buy Allergan for $66 billion, and its annual revenue is expected to exceed $25 billion. It is expected to be in the next year. 10.
JIANGSU CLS TECHNOLOGY CORP.LTD , https://www.js-cls.com